Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer

Next Previous
X
Search
Trial Profile

An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pamiparib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors BeiGene

    • Most Recent Events

    • 11 Jul 2023 Status changed from active, no longer recruiting to completed.
    • 05 Jun 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified 16 Jun 2021 ).
    • 29 Nov 2021 protocol amendment initiated a more proactive dose-modification algorithm for instances of hematologic AE

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top